Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Lydia Giles"'
Autor:
Rose Gunn, Maura Pisciotta, Rachel Gold, Arwen Bunce, Katie Dambrun, Erika K Cottrell, Danielle Hessler, Mary Middendorf, Miguel Alvarez, Lydia Giles, Laura M Gottlieb
Publikováno v:
Journal of the American Medical Informatics Association. 30:869-877
Objective Increased social risk data collection in health care settings presents new opportunities to apply this information to improve patient outcomes. Clinical decision support (CDS) tools can support these applications. We conducted a participato
Autor:
Ravi K. Amaravadi, Rosemarie Mick, Phyllis A. Gimotty, Jeffrey A. Sosman, Sunandana Chandra, Ann W. Silk, George Ansstas, Leonel F. Hernandez-Aya, Roman Groisberg, Andrew Kossenkov, Noelle Frey, Mary Carberry, Lydia Giles, Sheryl Mitnick, Giorgos C. Karakousis, Gerald P. Linette, Lynn M. Schuchter, Benjamin J. Kim, Tomas S. Aleman, Alexander C. Huang, Tara C. Mitchell, Janice M. Mehnert
Supplementary Data from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de3a6895864bb4c83269fb4d00361c5
https://doi.org/10.1158/1078-0432.22487202.v1
https://doi.org/10.1158/1078-0432.22487202.v1
Autor:
Ravi K. Amaravadi, Rosemarie Mick, Phyllis A. Gimotty, Jeffrey A. Sosman, Sunandana Chandra, Ann W. Silk, George Ansstas, Leonel F. Hernandez-Aya, Roman Groisberg, Andrew Kossenkov, Noelle Frey, Mary Carberry, Lydia Giles, Sheryl Mitnick, Giorgos C. Karakousis, Gerald P. Linette, Lynn M. Schuchter, Benjamin J. Kim, Tomas S. Aleman, Alexander C. Huang, Tara C. Mitchell, Janice M. Mehnert
Supplementary Figure from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2670c2d2b492c91d7dfa7fddb2ebee33
https://doi.org/10.1158/1078-0432.22487181.v1
https://doi.org/10.1158/1078-0432.22487181.v1
Autor:
Ravi K. Amaravadi, Rosemarie Mick, Phyllis A. Gimotty, Jeffrey A. Sosman, Sunandana Chandra, Ann W. Silk, George Ansstas, Leonel F. Hernandez-Aya, Roman Groisberg, Andrew Kossenkov, Noelle Frey, Mary Carberry, Lydia Giles, Sheryl Mitnick, Giorgos C. Karakousis, Gerald P. Linette, Lynn M. Schuchter, Benjamin J. Kim, Tomas S. Aleman, Alexander C. Huang, Tara C. Mitchell, Janice M. Mehnert
Purpose:Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day (D+T).Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6061b06ac5a9db3eba975350345c80e4
https://doi.org/10.1158/1078-0432.c.6532461.v1
https://doi.org/10.1158/1078-0432.c.6532461.v1
Autor:
Janice M. Mehnert, Tara C. Mitchell, Alexander C. Huang, Tomas S. Aleman, Benjamin J. Kim, Lynn M. Schuchter, Gerald P. Linette, Giorgos C. Karakousis, Sheryl Mitnick, Lydia Giles, Mary Carberry, Noelle Frey, Andrew Kossenkov, Roman Groisberg, Leonel F. Hernandez-Aya, George Ansstas, Ann W. Silk, Sunandana Chandra, Jeffrey A. Sosman, Phyllis A. Gimotty, Rosemarie Mick, Ravi K. Amaravadi
Publikováno v:
Clinical Cancer Research. 28:1098-1106
Purpose: Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day (D+T). Patient
Autor:
Josephine R. Giles, Sasikanth Manne, Elizabeth Freilich, Derek A. Oldridge, Amy E. Baxter, Sangeeth George, Zeyu Chen, Hua Huang, Lakshmi Chilukuri, Mary Carberry, Lydia Giles, Nan-Ping P. Weng, Regina M. Young, Carl H. June, Lynn M. Schuchter, Ravi K. Amaravadi, Xiaowei Xu, Giorgos C. Karakousis, Tara C. Mitchell, Alexander C. Huang, Junwei Shi, E. John Wherry
Publikováno v:
Immunity
The clinical benefit of T cell immunotherapies remains limited by incomplete understanding of T cell differentiation and dysfunction. We generated an epigenetic and transcriptional atlas of T cell differentiation from healthy humans that included exh
Autor:
Felix Quagliarello, Michael D. Farwell, Lydia Giles, Lakshmi Chilukuri, Qing Zhao, Sangeeth M. George, Melanie W. Kier, Shujing Liu, Patrick Yan, Lakshmanan Annamalai, Kurt D'Andrea, Suzanne McGettigan, Kristin Kreider, Wendy M. Blumenschein, Lynn M. Schuchter, Andrew Kozlov, Robin Mogg, Robert J. Orlowski, E. John Wherry, Bradley Wubbenhorst, Bertram Bengsch, Katherine L. Nathanson, Jennifer H. Yearley, Rosemarie Mick, Sasikanth Manne, Ramin S. Herati, Xiaowei Xu, Brandon Wenz, Tara C. Mitchell, Gerald P. Linette, Liza Dorfman, Alexander C. Huang, Adam A. Kraya, Ravi K. Amaravadi, Giorgos C. Karakousis, Wei Xu, Mary Carberry
Publikováno v:
Nature Medicine. 25:454-461
Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvir
Autor:
Steve Balian, Benjamin S. Abella, Olivia Doran, Mary Carberry, E. Paul Wileyto, Shaun K. McGovern, Phyllis A. Gimotty, Sunita D. Nasta, Ian Frank, Niraj Vyas, Matthew C. Hyman, Jonathan Kolansky, Edith Teng, Michael C. Milone, Nabil M Abdulhay, Paul Callahan, Sarah Gamblin, Lydia Giles, Ravi K. Amaravadi, Jennifer C. Walsh
BackgroundOlder patients are at risk of increased morbidity and mortality from COVID-19 disease due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There are few effective treatments for outpatients with COVID-19.ObjectiveTo evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbad9409d5cb28b82cd2ae5b6ed7187f
https://doi.org/10.1101/2021.02.22.21252228
https://doi.org/10.1101/2021.02.22.21252228
Autor:
Mary Carberry, Grayce N. Selig, Kristin Kreider, Suzanne McGettigan, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Wei Xu, Alexander C. Huang, Giorgos C. Karakousis, John N. Lukens, Lydia Giles, Cathy Zheng
Publikováno v:
Journal of Clinical Oncology. 38:10054-10054
10054 Background: Checkpoint blockade improves survival in patients with melanoma, with durable complete responses (CR) after stopping therapy. Based on data from KEYNOTE-001, immunotherapy is often continued for 24 months in patients with confirmed
Autor:
Suzanne McGettigan, Christopher J. Miller, Misha Rosenbach, Emily Y. Chu, Karolyn A. Wanat, Leslie A. Fecher, Lydia Giles, Ravi K. Amaravadi, Marcia S. Brose, John T. Seykora, Lynn M. Schuchter
Publikováno v:
Journal of the American Academy of Dermatology. 67:1265-1272
Background Vemurafenib, a novel selective small molecule inhibitor of BRAF, has recently been shown to be effective in the treatment of melanomas harboring the BRAF V600E mutation. Similar to the broad-spectrum RAF inhibitor sorafenib, vemurafenib in